Global Irritable Bowel Syndrome Market Status: The Prevalence is 10%-15%

Global Irritable Bowel Syndrome Market Overview

According to Global Market Monitor, the global irritable bowel syndrome market will be $1786.25 million in 2024 with a CAGR of 9.85% from 2024 to 2029.

Irritable bowel syndrome (IBS) is a gastrointestinal disorder that affects the large intestine, symptoms include abdominal pain, altered bowel habits, increased gas, bloating (distention), cramping, and food intolerance. Moreover, these symptoms occur over a long period. IBS is classified into three different types, IBS with constipation, IBS with diarrhea, and IBS with alternating constipation & diarrhea.

Severe infections, stressful lifestyles, changes in gut microbes, intestinal muscle contractions, and nervous system abnormalities often cause it. Several medications are currently available to relieve mild symptoms of IBS. Doctors also recommend the use of probiotics and mental health therapies such as cognitive behavioral therapy (CBT), gut-directed hypnotherapy, and relaxation training to treat certain patients.

IBS is one of the most common functional gastrointestinal disorders, with an estimated global prevalence of 10-15%. The exact cause of the symptoms is unknown, and symptoms can be caused by a disorder in the way the brain, nervous system, and gut interact. This can lead to changes in normal gut sensation and movement. About 20-40% of patient visits are due to symptoms of IBS. Most people with irritable bowel syndrome are under the age of 50, but many older people also suffer from the condition, whose effects can range from mild irritation to severe weakening. Patients with moderate to severe symptoms often hurt their physical, educational, social, psychological, and financial well-being.

However, many people still do not realize and diagnose that their symptoms indicate a medically recognized condition. As a result, many awareness campaigns are being organized to raise awareness of the disease. These campaigns and initiatives are expected to raise awareness of the disease and encourage patients to seek treatment for their disease. In turn, this is expected to accelerate the growth of the IBS therapy market.

Bausch Health Companies Inc. is one of the major players operating in the Irritable Bowel Syndrome market, holding 17.53% in 2023.Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology.

Company Name	Bausch Health Companies Inc.
Website	www.bauschhealth.com
Established Time	1983
Sales Regions	Worldwide
Business Overview	The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.